Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study
2023 / Nunes da Silva T, Rodrigues R, Saramago A, Pires C, Rito M, Horta M, Martins C, Leite V, Cavaco BM
"significant real-world efficacy of Dabrafenib plus Trametinib in both survival and recurrence compared with standard treatment, with a good safety profile"